The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 02, 2017

Filed:

Jan. 15, 2015
Applicant:

Universiteit Gent, Ghent, BE;

Inventors:

Kristien Rasschaert, Merelbeke, BE;

Bruno Goddeeris, Merelbeke, BE;

Eric Cox, Merelbeke, BE;

Dieter Deforce, Ghent, BE;

Assignee:

Universiteit Gent, Ghent, BE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 47/48 (2006.01); G01N 33/573 (2006.01); A61K 9/00 (2006.01); A61K 39/002 (2006.01); A61K 39/108 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/48415 (2013.01); A61K 9/0053 (2013.01); A61K 39/002 (2013.01); A61K 39/0258 (2013.01); A61K 39/3955 (2013.01); A61K 47/48561 (2013.01); A61K 47/48823 (2013.01); A61K 47/48876 (2013.01); A61K 47/48884 (2013.01); G01N 33/573 (2013.01); A61K 2039/542 (2013.01); A61K 2039/6056 (2013.01); G01N 2333/705 (2013.01); G01N 2333/948 (2013.01); G01N 2500/04 (2013.01);
Abstract

The invention is based on the identification of aminopeptidase N (APN) as the receptor for F4 fimbriae of enterotoxigenic(ETEC). Based on the observation that oral administration of F4 fimbriae induces a protective intestinal mucosal immune response against a subsequent challenge with F4 ETEC, and the observation that the internalization of said F4fimbriae is clathrin-mediated, the present invention provides the characterization of APN as a target useful in: in an in vitro assay to screen for molecules that are capable to mimic the clathrin-mediated F4 endocytosis; in an in vitro assay to screen for molecules that are capable to modulate the binding of F4 fimbriae with APN; in the development of a carrier for the delivery of antigens/therapeutics, i.e. immunomodulators to the intestinal submucosa or the intestinal mucosa-associated lymphoid tissue, wherein said carrier comprises an APN specific target molecule that mimics the clathrin-mediated F4 endocytosis. The use of the carriers thus identified or the treatments thus identified, in a method of inducing an antigen specific intestinal mucosal immune response, and/or in the treatment of bacterial diarrhea, is a further aspect of the present invention.


Find Patent Forward Citations

Loading…